Medicenna Therapeutics Corp. (TSE:MDNA – Get Free Report) shares traded up 0.6% during mid-day trading on Thursday . The company traded as high as C$1.91 and last traded at C$1.70. 102,231 shares were traded during mid-day trading, a decline of 5% from the average session volume of 107,412 shares. The stock had previously closed at C$1.69.
Medicenna Therapeutics Price Performance
The firm has a market capitalization of C$110.82 million, a P/E ratio of -3.82 and a beta of 1.21. The business’s 50-day simple moving average is C$2.14 and its 200 day simple moving average is C$2.18. The company has a quick ratio of 4.65, a current ratio of 2.51 and a debt-to-equity ratio of 0.06.
About Medicenna Therapeutics
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors.
Recommended Stories
- Five stocks we like better than Medicenna Therapeutics
- How to Invest in Blue Chip Stocks
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Freeport-McMoRan, Copper Demand Short-Term Pain, Long-Term Gain
- How to Find Undervalued Stocks
- Time to Load Up on Home Builders?
Receive News & Ratings for Medicenna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicenna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
